Question Bank › Second engine igniting off the first

Second engine igniting off the first

Second engine igniting off the first: an unplanned-for adjacent revenue stream has started paying, and management is now

Calls Tested
434
Answered YES
11
Hit Rate
2.5%
rare by design

Agios Pharmaceuticals, Inc. (AGIO) — this company's answers

NO on the Q3 2018 call 2018-11-01 C
The model's full reasoning — Q3 2018 call → NOWe need to determine if the transcript describes a second, distinct way of making money that emerged from existing operations, is already generating real paying business, and management is deliberately growing it. Let's analyze the transcript. The company is Agios, a biotech. They have products: TIBSOVO (ivosidenib) for AML, IDHIFA (enasidenib) for AML, and other pipeline drugs. They also have rare genetic disease programs (Mitapivat for PK deficiency, etc.). The question asks: "does management describe that a SECOND, DISTINCT WAY OF MAKING MONEY has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional revenue avenue that grew out of what the company already does rather than a separate diversification - AND that this second avenue is ALREADY GENERATING REAL PAYING BUSINESS today while management is now deliberately putting effort or resources behind growing it?" We need to look for a second revenue stream that is distinct from the core product sales. For example, licensing, royalties, or something like that. In the transcript, they mention revenue from TIBSOVO sales, IDHIFA royalties, and collaboration revenue. But are those distinct? IDHIFA is a product they developed and licensed to Celgene, so royalties are a revenue stream from that. But is that a "second avenue that grew out of the first"? Actually, IDHIFA is a separate product, not a second avenue from the same product. The question is about a second way of making money that emerged from existing operations, like monetizing a capability, data, etc. Let's read carefully. The transcript mentions: "Total revenue for the third quarter was $15 million, compared to revenue of $11 million for the third quarter of 2017. The year-over-year increase in revenue was driven by $4.5 million of net U.S. sales of TIBSOVO, a $1.3 million increase in the IDHIFA royalty, which was offset by a decrease in collaboration revenue recognized during the quarter." So they have product sales, royalties, and collaboration revenue. But are these distinct "ways of making money" that emerged from existing operations? The royalties from IDHIFA are from a product they developed and licensed. That is a separate product, not a second avenue from the same product.

← Back to the full AGIO analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that a SECOND, DISTINCT WAY OF MAKING MONEY has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional revenue avenue that grew out of what the company already does rather than a separate diversification - AND that this second avenue is ALREADY GENERATING REAL PAYING BUSINESS today while management is now deliberately putting effort or resources behind growing it? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent phenomenon with both halves present as a present-tense reality: (1) A SECOND EARNING AVENUE THAT GREW OUT OF THE FIRST. Management identifies an additional, distinguishable stream of business that arose from something the company already built or does - for example: monetizing a capability, technology, process, data, byproduct, or infrastructure that was originally created to serve the core business; the company's existing product or asset base opening a different kind of revenue (services on an installed base, licensing what it developed for itself, selling to a different side of its market, a spin-out offering born from internal tools, a byproduct or secondary output now being sold in its own right); or an offering originally built for one purpose now being sold as its own line of business. What matters is the ORIGIN - the second avenue leverages what already exists inside the company - and the DISTINCTNESS - management talks about it as its own stream of business, not just more sales of the same thing to the same buyers. (2) IT IS PAYING TODAY AND BEING FED. Management indicates that this second avenue is already producing real current revenue, orders, contracts, or paying customers in the recent period - actual money changing hands now, however small relative to the core - AND describes deliberate current effort to grow it: dedicating people, investment, capacity, or organizational focus to it; signing further deals in it; building it out; or explicitly treating it as a growth avenue the company is now pursuing on purpose. Answer NO if the company describes only one way of making money, however strong or fast-growing. NO if the additional avenue is only an idea, plan, pilot without paying customers, or an opportunity management says it could pursue someday. NO if the 'second stream' is ordinary cross-selling, upselling, product-line extensions, or new versions sold to the same customers in the same basic way. NO if the second business came chiefly from acquiring an unrelated company rather than emerging from the company's own operations. NO if management mentions the additional stream only in passing without conveying that it is real, paying, and being deliberately grown. NO if the company is a conglomerate or multi-segment business simply reporting its usual several segments. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
M Macy's, Inc. Q4 2022 2023-03-02 D
CMLS Cumulus Media Inc. Q3 2022 2022-10-28 D
GDRX GoodRx Holdings, Inc. Q2 2022 2022-08-08 F
SOPH SOPHiA GENETICS SA Q4 2021 2022-03-15 C
SLQT SelectQuote, Inc. Q2 2022 2022-02-07 F
LC LendingClub Corporation Q4 2021 2022-01-26 A
IRBT iRobot Corporation Q3 2021 2021-10-28 D
T AT&T Inc. Q3 2018 2018-10-24 C+
LRN Stride, Inc. Q1 2019 2018-10-23 B
MITK Mitek Systems, Inc. Q4 2017 2017-11-07 C+
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C

How the model reasoned

LRN · Q1 2019 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows career readiness as a distinct second revenue avenue that emerged directly from the existing MPS business: students already enrolled in Managed Public Schools are being moved into career readiness programs (over 5,000 students), and the initiative is built on the same platform, curriculum, and student base. Management explicitly describes it as a “career readiness line of business” and “robust career readiness business” that is already generating paying enrollments today while they are deliberately investing resources—dedicated executives, reallocation of funds, and plans to drive a major portion of next year’s enrollment growth.
M · Q4 2022 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows that Macy’s Marketplace is explicitly described as a distinct new revenue avenue that emerged directly from their existing e-commerce operations and customer base (macys.com, cross-shoppers, and omnichannel platform). Jeff Gennette states it “captures incremental sales opportunity,” “drives a larger average order value,” “allows us to quickly move into new and adjacent categories without inventory risk,” and “attracts a new younger customer,” while management is actively scaling it by adding 2,000 brands in 2023 and launching Bloomingdale’s marketplace in the back half.
GDRX · Q2 2022 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows that Pharma Manufacturer Solutions is the second distinct revenue avenue that emerged from GoodRx’s existing operations. Trevor explicitly states: “Our distinct ability to reach both consumers and providers continues to be recognized by manufacturers as evidenced by the strong growth.” This capability originated from the core prescription-transactions platform and user base 3 years earlier (when other offerings were only ~5% of revenue). In Q2 2022 it generated $26.6 million (102% YoY growth) and is already producing real paying business.

More from the question bank

Event-dense runwayThe leak is fixed: the company is keeping whBet-the-company financing already spent on hManagement is buying/committing capital at aScarcity of the company's own outputDemand pull is outrunning the plan for one sAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.